A Phase II/III Study of N 803 (ALT 803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non Small Cell Lung Cancer Previously Treated With Anti PD 1 or Anti PD L1 Therapy (Lung MAP Non Match Sub Study)
For more information about the trial above please contact the study team:
Principal Investigator, John Wrangle, at email@example.com.
Study Coordinator, Alexandra Leitner, at firstname.lastname@example.org, or please call +1 843-792-1507.
Trial opened at the following institutions: Medical University of South Carolina